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Mutations Recently, KIT mutations were found in 12.7-48.1% of adult acute myeloid leukemia (AML) patients. [1] [2] [3] [4] [5] [6] Our previous analysis revealed that KIT mutations were found in 8 (17.4%) of 46 pediatric t(8;21)-AML patients and these patients had the poorer prognosis than those without KIT mutations.
7 Recent Berlin-Frankfurt-Mü nster study and Dutch Childhood Oncology Group study revealed that 5 (31.3%) of 16 t(8;21)-AML patients had KIT mutations. 8 On the other hand, Children's Cancer Group study revealed that KIT mutations were not found in eight t(8;21)-AML patients. 9 There remains the possibility of the different frequency about KIT mutations in ages and races. Thus, we further investigated KIT mutations in a larger number of pediatric t(8;21)-AML patients.
We examined for KIT mutations in 42 newly diagnosed t(8;21)-AML patients who were treated on the same AML99 protocol from January 2003 to December 2006 after AML99 study closed. 7 We found KIT mutations in 6 (14.3%) of 42 t(8;21)-AML patients (D816mutation (Mt) (n ¼ 4), N822Mt (n ¼ 1), deletion of D419 (N ¼ 1) ).
Furthermore, we searched for other KIT mutations and found novel mutations in transmembrane domain (exon 10) in 3 (3.4%) of total 88 t(8;21)-AML patients, including previous 46 patients 7 (Table 1) . Two patients having the same I538V (ATT to GTT) in KIT have been in complete remission for 30 and 48 months, respectively. However, the remaining patient having V540L (GTG to CTG) in KIT relapsed 4 months after diagnosis. V540L was also found in relapsed bone marrow sample. These mutation sites were in the vicinity of the codon 541, which was reported as single nucleotide polymorphism (SNP) site (ATG to CTG, M541L). Therefore, we examined these mutations (I538V and V540L) and M541L (SNP) in 42 normal peripheral blood samples, and detected only M541L (SNP) in 4 (9.5%) samples. Internal tandem duplication of KIT 10 was not found in this study. In total, KIT mutations were found in 17 (19.3%) of 88 t(8;21)-pediatric AML patients (Table 1 ). This frequency was lower than that of several adult reports including Japan. [1] [2] [3] 5 Interestingly, in Europe, D816Mt and N822Mt were found in 5 and 0 of 47 adult patients in Netherlands, 1 3 and 0 of 56 adult patients in France, 5 12 and 0 of 42 adult patients in Italy, respectively. 6 On the other hand, in east Asia, D816Mt and N822Mt were found in 7 and 3 of 37 adult patients in Japan, 3 9 and 10 of 54 adult patients in China, 2 respectively. Our study revealed that D816Mt and N822Mt were found in 6 and 5 of 88 t(8;21)-pediatric AML patients, respectively. The frequency of N822Mt in KIT is different between Europe (Caucasian) and east Asia (oriental people). Boissel et al. 5 suggested that ethnic and geographic variations may also be responsible for such disparities. N822Mt in KIT was frequent in Japanese and Chinese t(8;21)-AML patients. Notably, Wang et al. 2 suggested that Imatinib, a tyrosine kinase inhibitor, has the efficacy for the leukemic cells with N822Mt, but not with D816Mt. Further larger study is needed to clarify N822Mt and the efficacy of Imatinib. Abbreviations: AML, acute myeloid leukemia; Mt, mutation.
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